Kornimate/medical-research-clean huggingface dataset:
lung protective ventilation in pulmonary thromboendarterectomy (pte) patients

Conditions: Chronic Thromboembolic Pulmonary Hypertension; Acute Lung Injury

Summary: chronic thromboembolic pulmonary hypertension (cteph) is caused by unresolved thromboemboli in the pulmonary arteries, which lead to pulmonary hypertension and, left untreated, right heart failure. this disease can be potentially cured by performing a pulmonary thromboendarterectomy (pte) to remove the blood clots. the surgery is not without risk and the most worrisome complication is the development of a form of acute lung injury called reperfusion lung injury, which occurs in about 40 percent of patients. the landmark publication of the ardsnet study demonstrated that a low tidal volume strategy of mechanical ventilation, decreased morbidity and mortality in patients who had acute respiratory distress syndrome (ards). since then there have been some studies examining the role of a low tidal volume strategy in all patients who are mechanically ventilated. some studies have demonstrated a decreased incidence of acute lung injury while others have failed to do the same. in patients at high risk for developing acute lung injury, such as patients undergoing pte, there may be a benefit to using low tidal volumes to reduce the incidence of reperfusion lung injury. to assess the efficacy of a low tidal volume ventilation strategy in patients undergoing pte, 134 patients will be randomized at the time of surgery to either low tidal volumes (6ml/kg of ideal body weight), or standard tidal volumes (10ml/kg of ideal body weight). patients will be followed clinically to assess for the development of reperfusion lung injury. this will be defined as the development of hypoxemia (pao2/fio2 ratio less than 300) and chest infiltrates in the area of reperfused lung with no other identifiable etiology within the first 72 hours of surgery. patients will also be assessed for other factors known to contribute to acute lung injury including: plateau pressures, peak inspiratory pressures, fluid balance, and number of transfusions received. secondary endpoints of the study will be: time to successful spontaneous breathing trial, ventilator free days, icu free days, hospital free days, and mortality.


Eligibility criteria:
inclusion criteria: * age 18 years of age * evidence of cteph * acceptable surgical candidate exclusion criteria: * bmi \> 40 * patient undergoing lung biopsy or cabg at time of surgery

Keywords: chronic thromboembolic pulmonary hypertension lung injury ventilation strategies
efficacy, safety and immunogenicity of rotavirus rv3 vaccine (bio farma) in neonates

Conditions: Rotavirus Gastroenteritis

Summary: this phase iii trial aims to assess the efficacy, safety and immunogenicity of rotavirus rv3 vaccine (bio farma) in neonates, lot-to-lot consistency, and antigen interference with co-administered epi vaccines

this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity following three doses of rotavirus rv3 vaccine (bio farma) administered as a neonatal schedule

Eligibility criteria:
inclusion criteria: 1. neonate 0-5 days (0-144 hours) of age at the time of first dose. 2. neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator. 3. the neonate was born full term (minimum of 37 completed weeks and maximum of 42 completed weeks gestation). 4. neonate birth weight 2500-4000 g inclusive. 5. parent or guardian has been informed properly regarding the study and signed the informed consent form. 6. parent or guardian commits to comply with the instructions of the investigator and the schedule of the trial. exclusion criteria: 1. subject concomitantly enrolled or scheduled to be enrolled in another trial. 2. the subject has direct relatives relationship with the study team. 3. the subject has evolving mild, moderate or severe illness, especially infectious diseases or fever (body temperature 37.5°c) within the 48 hours preceding enrollment. 4. subject with a known or suspected history of allergy to any component of the vaccines (based on anamnesis). 5. subject with a biological mother with a known or suspected human immunodeficiency virus (hiv) or hepatitis b infection. 6. subject with known or suspected major congenital malformations or genetically determined disease. 7. subject with intussusception. 8. subject with a known or suspected disease of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy. 9. subject with a known or suspected disease of the immune system or those who have received immunosuppressive therapy, including immunosuppressive courses of systemic corticosteroid. 10. subject who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product is anticipated during the course of study. 11. any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives. 12. subject immunized with non-epi vaccines. 13. gastroenteritis in the 24 hours preceding dosing (temporary exclusion criteria). 14. subject planning to move from the study area before the end of the study period.

Keywords: rotavirus vaccine
gabapentin in patients at clinical risk for psychosis

Conditions: Clinical High Risk for Psychosis

Summary: the purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.

six week, single site, proof-of concept, randomized double-blind placebo-controlled pilot study to examine the effects of moderate dose gabapentin (3600mg) in n= 100 putatively prodromal patients on hippocampal activity.

Eligibility criteria:
inclusion criteria: 1. cope patient between age of 18-30 2. capacity to give informed consent 3. currently using a reliable method of birth control (female) (condom plus spermicide, diaphragm plus spermicide, iud, birth control pills, norplant, vasectomy in partner) exclusion criteria: 1. metal implants in body or a history of metal working, or more than one past mri scan with gadolinium 2. lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity to contrast agents 3. lifetime diagnosis of renal failure/disease 4. acute neurological, neuroendocrine,or medical disorder including renal insufficiency 5. lifetime diagnosis of hypertension or diabetes 6. intelligence quotient (iq) \< 70 7. acute risk for suicide and/or violence 8. pregnant, lactating 9. current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics) 10. current use or anticipated need for antipsychotics or mood stabilizers (all antipsychotics, also depakote, lithium, lamotrigine, pregabalin or any med with a mechanism of action like gabapentin) 11. the clinical global impressions scale (cgi)-improvement score during study equal to or greater than 6
development of bone grafts using adipose derived stem cells and different scaffolds

Conditions: Overweight

Summary: the repair of large osseous defects remains still unsolved. aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.


Eligibility criteria:
inclusion criteria: * german-speaking patients aged 18-70 admitted to the clinic of reconstructive surgery for reconstructive surgery and fat-excision. exclusion criteria: * drug-abuse, neoplasia and metabolic disorders
proctologic practice and covid-19

Conditions: Proctologic Practice During COVID-19

Summary: cross-sectional non-incentivized worldwide web survey. a worldwide survey of 1050 respondents showed that proctologic practice has been seriously affected by the pandemic. age, gender and level of hospital preparedness predicted the change of status of surgical and outpatient activities. the results of our study may inform the development of strategies to reopen activities while protecting frontline healthcare workers.

a 27-item survey (namely, 'proctolock 2020') was designed and developed by the authors using an online platform ('online surveys' \[formerly bos - bristol online survey\], developed by the university of bristol) in accordance with the american association for public opinion research (aapor) guidelines and the checklist for reporting results of internet e-surveys \[cherries\]

Eligibility criteria:
inclusion criteria: members of renowned scientific societies with an interest in coloproctology

Keywords: proctology covid-19
a study of rc48-adc in local advanced or metastatic gastric cancer subjects with the overexpression of her2

Conditions: Gastric Cancer; HER2 Overexpressing Gastric Carcinoma

Summary: this study will evaluate the efficacy and safety of intravenous rc48-adc in local advanced or metastatic gastric patients with the overexpression of her2.


Eligibility criteria:
inclusion criteria: * voluntary agreement to provide written informed consent. * male or female, age ≥ 18 years and ≤ 80 years. * predicted survival ≥ 12 weeks. * eastern cooperative oncology group (ecog) performance status score of 0 or 1. * all female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.female subjects of child-bearing potential must agree to use two forms of highly effective contraception. male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception. * willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol. * adequate organ function. * have had progression or intolerance following receipt of at least two systemic chemotherapy for advanced or metastatic disease. * her2 overexpression defined as her2 ihc 2+ or 3+. * measurable disease according to recist 1.1. exclusion criteria: * known hypersensitivity to recombinant humanized anti-her2 monoclonal antibody-mmae conjugate for injection. * history of receiving any anti-cancer drug/biologic treatment within 4 weeks prior to trial treatment. * history of major surgery within 4 weeks of planned start of trial treatment. * has received a live virus vaccine within 4 weeks of planned start of trial treatment. * has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. * history of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above. * assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Keywords: rc48-adc her2 overexpression gastric cancer
evaluating the health outcomes of the joslin why wait? program

Conditions: Diabetes; Obesity

Summary: evaluating the health outcomes of patients that were enrolled in joslin's why wait program. these outcomes include bmi, a1c, lipid profile.

this study is aimed to evaluate the health outcomes of patients enrolled in joslin's why wait program. this program aims to control diabetes and help patients lose weight.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes with bmi over 35 exclusion criteria: * patients with type 1 diabetes
novel electrolyzed water spray treatment mild dermatophytosis

Conditions: Dermatophytoses

Summary: the purpose of this study is to test whether spraying the skin of patients of patients by use of the novel electrolyzed water spray will produce improvement in the condition of mild dermatophytosis.

in this study, water inculding tap water,pure water and salt water, and an apparatus for producing electrolyzed water (https://www.deposon.com.cn; https://www.deposon.com）were used to generate an electrolyzed water mist spray or spray. this instantly generated electrolyzed water mist spray or spray has oxidation-reduction potential (orp) ≥1200mv,and contains non-specific total oxidation capacity which equals to 0.28±0.10ppm,0.06±0.04ppm and 3.92±0.39ppm of desolved ozone. this instantly generated electrolyzed water mist spray or spray does not release detectable ≥0.1mg/m3 of gaseous ozone. this instantly generated electrolyzed water mist spray or spray has ph 8.4±0.4 and releases negative air ion.the apparatus for producing electrolyzed water has a positive electrode which is covered by a conductive diamond material (patent# cn215308550u).this is an open-label, single-arm, and before and after treatment comparison study. this study uses this novel electrolyzed water device and the water spray to treat mild dermatophytosis.

Eligibility criteria:
inclusion criteria: * mild dermatophytosis accompanied by significant itching symptom * patient \> 18 years old. exclusion criteria: * severe dermatophytosis. * 80 years or older. * pregnant or breastfeeding women.

Keywords: electrolyzed water device hydroxyl radical tap water spray dermatophytosis itching
a mind-body medicine curriculum for peer counselors

Conditions: Anxiety

Summary: this study will evaluate a mind-body medicine curriculum for high school peer counselors in order to answer the following research questions: 1. will peer counselor participation in the mind-body medicine curriculum increase their sense of self-regulation, responsibility, social competence, and empathy; decrease anxiety; and increase hope? 2. what are the experiences of peer support counselors participating in the mind-body medicine curriculum?

the study will be done at the marjory stoneman douglas high school. the research will use a mixed-methods design by collecting both quantitative and qualitative data. the quantitative data will be in the form of standardized research instruments and the qualitative data will be gathered through focus group interviews with the peer-counselors.

Eligibility criteria:
inclusion criteria: • all high school students who are participating in the peer counseling program at marjory stoneman douglas high school exclusion criteria: • none (as long as the students meet the inclusion criteria)

Keywords: empathy hope
a randomized controlled trial to assess the effect of l-carnitine in patients with diabetic peripheral neuropathy to relief pain and symptom improvement

Conditions: Patient Compliance

Summary: diabetic peripheral neuropathy (dpn) is a common complication of diabetes mellitus. the prevalence rate is approaching towards a peak throughout the world including bangladesh. the current intervention used in peripheral neuropathy does not bring satisfactory result. recent trial shows that l-carnitine is effective and safe in dpn. so it is expected that l-carnitine may produce better effect in compared to other medicine used previously for alleviation of dpn.

: diabetic peripheral neuropathy is one of the common complication of chronic diabetes mellitus, with a 30-50 % prevalence. progressive development of pain, numbness in toes or feet and sensory motor disorders affects the patient's quality of life. the epidemic spread of the disease has raised concern among physicians and researchers. a variety of agents or medicines with potential effect have been studied to control development of peripheral neuropathy. the existing management are yet unsatisfactory. recent studies have suggested that l-carnitine is potential to alleviate symptoms in patents with diabetic neuropathy. previous trial also indicated the efficacy and safety of l-carnitine on diabetic neuropathy. this limitations have led to search for an effective and tolerable option by placebo controlled trial.the present study is an attempt to investigate the effects of carnitine on pain and symptom improvement of diabetic peripheral neuropathy.

Eligibility criteria:
inclusion criteria: i. clinically diagnosed diabetic patients who had been on stable antidiabetic therapy for 1 year ii.age: 18 years to 70 years iii. patients hba1c level \<10 exclusion criteria: i. patient who are suffering from other causes of peripheral neuropathy for example chemotherapy and hiv patient, rheumatoid arthritis, sle, alcololism, vitamin b12 deficiency etc ii. lactating and pregnant women iii. patients taking anticonvulsants, antidepressants, opoioids and other neuropathic pain medication agents

Keywords: dpn, levocarnitine
rosuvastatin effect on telomere-telomerase system in acs

Conditions: Telomere Shortening; Telomere Length, Mean Leukocyte; 22q Telomere Deletion Syndrome

Summary: coronary heart disease (chd) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. the mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. telomere length and telomerase activity, therefore, correlates with the risk of chd and atherosclerosis. a present study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. this suggests a positive relationship of telomere and telomerase system with the treatment with statins in chd patients.

coronary heart disease (chd) is identified as one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. premature biological aging is distinct from chronological aging and may predispose the individual to myocardial infarction, atherosclerosis and chd in particular. the mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. telomere length and telomerase activity, therefore, correlates with the risk of chd and atherosclerosis. statins serve as the drugs of obvious choice based on their well established efficacy and safety profiles for the treatment of chd and associated atherosclerosis. a present clinical study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. this suggests a positive relationship of telomere and telomerase system with the risk of chd and, therefore, would help clinicians to categorise the patient populations based on their leucocyte telomere length for treatment with statins.

Eligibility criteria:
inclusion criteria: * subjects with acs, planing for pci treatment * male or females who are 18-80years of age * no current or previous statin therapy * no current indication for statin therapy (coronary artery disease; hypercholesterolemia, renal dysfunction) * subjects who have given their signed consent to participate in the study exclusion criteria: * patient \ 80 years * renal dysfunction * hyperlipidemia * active myositis * all forms of liver disease * pregnancy * breastfeeding * patients being treated with other type statin

Keywords: telomere telomerase statin percutaneous coronary intervention acute coronary syndrome
the value of supervised exercise therapy after invasive treatment of peripheral arterial disease

Conditions: Peripheral Arterial Disease

Summary: the objective of this study is to investigate what the value is of set after a radiological or surgical intervention for peripheral arterial disease in the aorto-iliacal, femoro-popliteal and crural segments in comparison with a control group.

treatment of peripheral arterial disease consists of vascular risk factor management and, dependent on the severity of the disease, exercise therapy, and either radiological or surgical intervention. after invasive treatment, many patients keep complaints, or complaints return, despite the fact that the treated segment is still patent. supervised exercise therapy (set) has been proved to be an effective treatment for patients with intermittent claudication, with a significant increase in maximal walking distance. further, exercise therapy contributes to an improvement in quality of life, a delay in disease progression and an improvement of the vascular risk profile. research on set after an invasive intervention is rare. in one study, the effect of set after surgical treatment on walking distance was determined. the initial claudication distance increased significantly in the exercise group, compared with surgical treatment alone. in june 2004, the network for exercise therapy parkstad (netp) was implemented in heerlen and its environs. the physiotherapists of this network provide community based set according to the protocol of the royal dutch society of physiotherapy. the web based database, which is a part of the netp, was retrospectively searched for patients who started set within 2 months after a radiological or surgical intervention. seventeen patients fulfilled these criteria, and after 1, 3, 6 and 12 months, there was a significant increase in both initial claudication distance (icd) and absolute claudication distance (acd). the expectation is that set, immediately offered after an invasive intervention for peripheral arterial disease, influences walking distance and quality of life. further, a positive influence on vascular risk factors and the frequency of re-interventions is expected.

Eligibility criteria:
inclusion criteria: * pad stage 2 or 3 according to fontaine, * surgical or radiological intervention indicated exclusion criteria: * no insurance for physiotherapy, * insufficient command of the dutch language, * serious cardiopulmonary limitations (nyha 3-4,) * major amputation, * serious co-morbidity prohibiting physical training

Keywords: peripheral arterial disease exercise therapy angioplasty bypass surgery
cervical cancer susceptible population classification

Conditions: Cervical Cancer Susceptible Population Classification

Summary: cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of hpv vaccines. recent genome-wide association studies (gwas) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. however, many reports lack clarity, consistency, and validation. in this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.


Eligibility criteria:
inclusion criteria: 1. subjects aged \>=18 years at time of consent 2. intended to undergo screening colposcopy 3. considered by a physician or healthcare provider as being of "average risk" for cervical cancer 4. willing to consent to blood draw cervical disease treatments 5. willing to sonsent to follow-up for five years as per protocol exclusion criteria: 1. history of cervical cancer 2. history of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study) 3. currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs. 4. any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent 5. known medical condition which, in the opinion of the investigator, should preclude enrollment into the study